CareerBliss has announced the 5th annual CareerBliss 50 Happiest Companies in America awards list. The list honors the top companies dedicated to creating happier work environments - as voted for by their own employees.
Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in...
Johnson & Johnson will start safety testing in early January on a vaccine combination that...
Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer ImmunotherapiesOctober 17, 2014 8:40 am | News | Comments
Under the agreement, facilitated by the Johnson & Johnson Innovation center in California,...
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® and IMBRUVICA® in Non-Hodgkin LymphomaOctober 14, 2014 8:48 am | News | Comments
The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Johnson & Johnson has reported third-quarter earnings of $4.75 billion. The results topped Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. The deal includes Alios' portfolio of potential therapeutics for viral infections.
Johnson & Johnson will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak.
Johnson & Johnson is asking surgeons not to use a line of devices for removing growths from the uterus amid regulators' growing concern that the electronic surgical tools raise the risk of spreading cancer to other parts of the body.
Johnson & Johnson, the world's biggest maker of health care products, plans to buy back up to $5 billion of the company's common stock. The maker of prescription drugs, medical devices and Tylenol said Monday that its board of directors had approved the stock buyback program.
The New Brunswick, New Jersey-based company said earnings increased to $4.33 billion, or $1.51 per share, from $3.83 billion, or $1.33 per share, in the same quarter a year ago.
Ortho-Clinical Diagnostics Announces Executive Leadership Additions as It Becomes an Independent, Stand-Alone CompanyJuly 8, 2014 8:58 am | News | Comments
Ortho-Clinical Diagnostics, Inc. unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group from Johnson & Johnson.
The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5 million for filling opioid prescriptions since 2007. It alleges the pharmaceutical companies' marketing of opioids for long-term use to treat non-cancer pain was false, misleading and "unsupported by science."
China has fined Johnson & Johnson, Nikon and five other foreign makers of eyeglasses and contact lenses on price-fixing charges in its latest effort to use anti-monopoly law to control consumer prices.
Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.
Johnson & Johnson is halting sales of devices used to remove growths in the uterus following a government warning that the electronic surgical tools can inadvertently spread cancer to other parts of the body. The announcement comes one week after the Food and Drug Administration discouraged doctors from using the devices, known as laparoscopic power morcellators.
Johnson & Johnson said Friday that European Union regulators approved a pill that combines its diabetes drug Invokana with metformin, an older treatment for the disease. Janssen-Cilag International will market the drug under the name Vokanamet.
Johnson & Johnson CEO Alex Gorsky says all three of its business segments are doing well and made significant medical advances last year.
Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.
Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal.
Johnson & Johnson has entered a multi-year agreement to be the Official Healthcare Partner of the USO. The announcement was made today during a ceremony to mark the opening of the USO's Warrior and Family Center at Bethesda, located on the campus of Naval Support Activity Bethesda, home of Walter Reed National Military Medical Center.
Johnson & Johnson today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments.
Lawyers and advocates for women alleging Johnson & Johnson products injured them are urging the U.S. Justice Department to investigate their claims the health care giant deliberately destroyed many documents critical to the lawsuits.
The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of the antipsychotic drug Risperdal. The court ruled that the state improperly sued under a law that applies to health care facilities, not pharmaceutical companies.
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price.
The British consumer goods company Reckitt Benckiser is buying K-Y personal lubricants from U.S. health care giant Johnson & Johnson. Terms of the deal were not disclosed Monday by Reckitt Benckiser, which expects to close the acquisition by the middle of the year.
Subsidiaries of Johnson & Johnson have agreed to pay $5.9 million to settle a lawsuit with Montana over how an anti-psychotic drug was marketed, state Attorney General Tim Fox said Thursday. The settlement with Janssen Ortho LLC and Janssen Pharmaceuticals closes the latest in a string of...
The contractor working for New Jersey's largest utility at the site of a town house explosion that killed one resident recently had been fined more than $100,000 by safety regulators for problems at two other sites, but the utility said Wednesday it never had any problems with the construction...
A lawyer for two drug companies told the Arkansas Supreme Court that the state improperly relied on federal regulations in a lawsuit that resulted in a $1.2 billion award over the companies' marketing of an antipsychotics drug.
- Page 1